As this happened, Piper Sandler upgraded its ImmunityBio Inc [IBRX] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. BTIG Research began covering IBRX with “Buy” recommendation on January 10, 2025. Piper Sandler revised its rating on May 12, 2023. It rated IBRX as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of IBRX
On Tuesday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock jump 3.57% to $2.90. Over the last five days, the stock has gained 15.54%. ImmunityBio Inc shares have risen nearly 13.28% since the year began. Nevertheless, the stocks have fallen -62.58% over the past one year. While a 52-week high of $7.64 was reached on 02/19/25, a 52-week low of $1.83 was recorded on 05/07/25. SMA at 50 days reached $2.66, while 200 days put it at $3.49.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 2.77, which if violated will result in even more drops to 2.64. On the upside, there is a resistance level at 3.04. A further resistance level may holdings at 3.19. The Relative Strength Index (RSI) on the 14-day chart is 60.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.44, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 12.65%. Stochastics %K at 90.23% indicates the stock is a selling.
The most recent change occurred on August 03, 2022 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
